Profile data is unavailable for this security.
About the company
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
- Revenue in SEK (TTM)22.12bn
- Net income in SEK2.41bn
- Incorporated1939
- Employees1.77k
- LocationSwedish Orphan Biovitrum AB (publ)Tomtebodavagen 23ASOLNA 171 65SwedenSWE
- Phone+46 86972000
- Websitehttps://www.sobi.com/
More ▼
Mergers & acquisitions
| Acquired company | SOBI:STO since announced | Transaction value |
|---|---|---|
| CTI Biopharma Corp | 4.21% | 1.33bn |
Data delayed at least 15 minutes, as of Apr 18 2024 17:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bavarian Nordic A/S | 11.05bn | 2.31bn | 18.21bn | 1.38k | 7.66 | 1.12 | 5.74 | 1.65 | 19.46 | 19.46 | 92.83 | 132.47 | 0.5281 | 1.92 | 6.10 | 5,121,349.00 | 11.03 | 1.21 | 13.62 | 1.48 | 65.18 | 53.72 | 20.89 | 4.06 | 1.35 | -- | 0.0139 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Vitrolife AB | 3.51bn | -3.85bn | 24.69bn | 1.08k | -- | 1.94 | -- | 7.03 | -28.44 | -28.44 | 25.94 | 93.96 | 0.1905 | 3.75 | 7.34 | 3,254,866.00 | -20.88 | -4.57 | -21.58 | -4.78 | 56.32 | 58.38 | -109.65 | -21.89 | 2.69 | -28.98 | 0.141 | -- | 8.60 | 24.99 | -1,077.41 | -- | -7.95 | 3.30 |
| Camurus AB | 1.72bn | 431.44m | 28.69bn | 213.00 | 66.42 | 18.55 | 64.40 | 16.71 | 7.49 | 7.49 | 30.11 | 26.84 | 1.07 | 1.17 | 7.29 | 8,060,329.00 | 26.85 | -1.13 | 33.67 | -1.41 | 92.87 | 90.05 | 25.13 | -1.63 | 4.13 | -- | 0.0162 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| ALK-Abello A/S | 7.55bn | 760.50m | 40.00bn | 2.82k | 60.32 | 6.28 | 32.90 | 5.30 | 2.09 | 2.09 | 20.90 | 20.10 | 0.7402 | 1.32 | 6.11 | 1,708,215.00 | 7.46 | 3.50 | 9.42 | 4.37 | 62.91 | 60.66 | 10.07 | 5.07 | 1.18 | 35.05 | 0.1468 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
| Orion Oyj | 13.89bn | 2.53bn | 53.55bn | 3.63k | 20.90 | 5.10 | 17.38 | 3.85 | 1.55 | 1.55 | 8.49 | 6.34 | 0.8088 | 1.57 | 5.56 | 327,588.10 | 14.72 | 19.47 | 18.03 | 24.16 | 55.30 | 59.38 | 18.20 | 20.71 | 1.75 | 94.79 | 0.1835 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| Zealand Pharma A/S | 536.40m | -1.10bn | 58.67bn | 253.00 | -- | 21.94 | -- | 109.38 | -12.57 | -12.57 | 6.01 | 27.28 | 0.1948 | 4.16 | 289.88 | 1,354,889.00 | -39.99 | -42.74 | -46.30 | -50.24 | 87.39 | 96.13 | -205.30 | -464.66 | 6.23 | -- | 0.0696 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
| Swedish Orphan Biovitrum AB (publ) | 22.12bn | 2.41bn | 90.65bn | 1.77k | 35.19 | 2.57 | 16.26 | 4.10 | 7.27 | 7.27 | 67.83 | 99.68 | 0.3497 | 1.38 | 4.25 | 12,484,200.00 | 3.80 | 5.93 | 5.20 | 7.60 | 77.57 | 77.42 | 10.88 | 16.61 | 0.4607 | 4.04 | 0.3769 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
| Genmab A/S | 25.78bn | 6.81bn | 207.67bn | 2.20k | 30.39 | 4.15 | -- | 8.06 | 66.05 | 66.05 | 249.95 | 483.85 | 0.5037 | -- | 3.09 | 7,474,592.00 | 13.31 | 17.43 | 14.25 | 18.59 | 55.82 | -- | 26.42 | 35.87 | 13.32 | -- | 0.0238 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
Data as of Apr 18 2024. Currency figures normalised to Swedish Orphan Biovitrum AB (publ)'s reporting currency: Swedish Krona SEK
19.05%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 Dec 2022 | 21.05m | 5.94% |
| Polar Capital LLPas of 29 Feb 2024 | 8.27m | 2.33% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 7.06m | 1.99% |
| Swedbank Robur Fonder ABas of 31 Dec 2022 | 6.37m | 1.80% |
| Handelsbanken Fonder ABas of 31 Dec 2022 | 6.34m | 1.79% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 5.30m | 1.50% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 4.03m | 1.14% |
| Artisan Partners LPas of 31 Dec 2023 | 3.46m | 0.98% |
| Lannebo Fonder ABas of 31 Dec 2023 | 2.87m | 0.81% |
| Cliens Kapitalf�rvaltning ABas of 31 Mar 2024 | 2.75m | 0.78% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
